A Formulated TLR7/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Van Hoeven, Neal ^a   Fox, Christopher B ^a   Granger, Brian ^a   Evers, Tara ^a   Joshi, Sharvari W ^a   Nana, Ghislain I ^a   Evans, Sarah C ^a   Lin, Susan ^a   Liang, Hong ^a   Liang, Li ^b   Nakajima, Rie ^b   Felgner, Philip L ^b   Bowen, Richard A ^c   Marlenee, Nicole ^c   Hartwig, Airn ^c   Baldwin, Susan L ^a   Coler, Rhea N ^a   Tomai, Mark ^d   Elvecrog, James ^d   Reed, Steven G ^a   Carter, Darrick ^a   more..

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

AGONISTS; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H5N1);

ADJUVANTS, IMMUNOLOGIC; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 85038829094     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46426     Document Type: Article

References (64)

1. Guan, Y. & Smith, G. J. The emergence and diversification of panzootic H5N1 influenza viruses. Virus Res 178, 35-43, doi: 10.1016/j.virusres.2013.05.012 (2013).
2. Sonnberg, S., Webby, R. J. & Webster, R. G. Natural history of highly pathogenic avian influenza H5N1. Virus Res 178, 63-77, doi: 10.1016/j.virusres.2013.05.009 (2013).
3. WHO. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO, http://www.who.int/influenza/human-animal-interface/H5N1-cumulative-table-archives/en/ (2016).
4. Herfst, S. et al. Airborne transmission of inflluenza A/H5N1 virus between ferrets. Science 336, 1534-1541, doi: 10.1126/science.1213362 (2012).
5. Imai, M. et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486, 420-428, doi: 10.1038/nature10831 (2012).
6. Zhang, Y. et al. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science 340, 1459-1463, doi: 10.1126/science.1229455 (2013).
7. Black, S. et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30, 1081-1085, doi: 10.1097/INF.0b013e3182367662 (2011).
8. Pedersen, G. K. et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine 32, 4550-4557, doi: 10.1016/j.vaccine.2014.06.009 (2014).
9. Reber, A. & Katz, J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 12, 519-536, doi: 10.1586/erv.13.35 (2013).
10. Stephenson, I. et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 15, 1252-1259, doi: 10.3201/eid1508.081754 (2009).
11. Jennings, L. C., and Monto, A. S., Chan, P. K., Szucs, T. D. & Nicholson, K. G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8, 650-658, doi: 10.1016/S1473-3099(08)70232-9 (2008).
12. Belshe, R. B. et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 203, 666-673, doi: 10.1093/infdis/jiq093 (2011).
13. Treanor, J. J., and Campbell, J. D., Zangwill, K. M., Rowe, T. & Wolff, M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354, 1343-1351, doi: 10.1056/NEJMoa055778 (2006).
14. Treanor, J. J. et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732-1737 (2001).
15. Luke, C. J. & Subbarao, K. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Rev Vaccines 13, 873-883, doi: 10.1586/14760584.2014.922416 (2014).
16. Landry, N. et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5, e15559, doi: 10.1371/journal.pone.0015559 (2010).
17. Ikeno, D. et al. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol 54, 81-88, doi: 10.1111/j.1348-0421.2009.00191.x (2010).
18. Belshe, R. B. et al. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA 312, 1420-1428, doi: 10.1001/jama.2014.12609 (2014).
19. Herbinger, K. H. et al. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59(R): adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults. Hum Vaccin Immunother 10, 92-99, doi: 10.4161/hv.26495 (2014).
20. Stavaru, C. et al. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Hum Vaccin Immunother, 1-18, doi: 10.1080/21645515.2015.1111495 (2015).
21. Bihari, I., Panczel, G., Kovacs, J., Beygo, J. & Fragapane, E. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. Clin Vaccine Immunol 19, 1943-1948, doi: 10.1128/CVI.00373-12 (2012).
22. Vesikari, T. et al. Safety and immunogenicity of an MF59((R))-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 30, 1388-1396, doi: 10.1016/j.vaccine.2011.12.009 (2012).
23. Czajka, H. et al. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. J Prev Med Hyg 53, 136-142 (2012).
24. Nolan, T. et al. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children < 3 years of age. J Infect Dis 210, 1800-1810, doi: 10.1093/infdis/jiu359 (2014).
25. Diez-Domingo, J. et al. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. Influenza Other Respir Viruses 9, 68-77, doi: 10.1111/irv.12295 (2015).
26. Kosalaraksa, P. et al. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial. J Infect Dis 211, 801-810, doi: 10.1093/infdis/jiu548 (2015).
27. Godeaux, O. et al. Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years. Vaccine 33, 2189-2195, doi: 10.1016/j.vaccine.2014.07.062 (2015).
28. Chen, W. H. et al. Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant. Open Forum Infect Dis 1, ofu091, doi: 10.1093/ofd/ofu091 (2014).
29. Moris, P. et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 31, 443-454, doi: 10.1007/s10875-010-9490-6 (2011).
30. Izurieta, P., Uy-Aragon, M. J., Drame, M. & Vaughn, D. W. Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age. Pediatr Infect Dis J 35, e35-47, doi: 10.1097/INF.0000000000000968 (2016).
31. Gillard, P. et al. An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respir Viruses 7, 55-65, doi: 10.1111/j.1750-2659.2012.00349.x (2013).
32. Chen, W. H. et al. Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vaccine Immunol 23, 73-77, doi: 10.1128/CVI.00475-15 (2015).
33. Khurana, S. et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 3, 85ra48, doi: 10.1126/scitranslmed.3002336 (2011).
34. Khurana, S. et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2, 15ra15, doi: 10.1126/scitranslmed.3000624 (2010).
35. Khurana, S. et al. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. PLoS One 9, e95496, doi: 10.1371/journal. pone.0095496 (2014).
36. O'Hagan, D. T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 6, 699-710, doi: 10.1586/14760584.6.5.699 (2007).
37. Zhang, A. J. et al. Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice. Clin Vaccine Immunol 21, 570-579, doi: 10.1128/CVI.00816-13 (2014).
38. Lai, C. H. et al. Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection. Vaccine 33, 4321-4329, doi: 10.1016/j.vaccine.2015.03.082 (2015).
39. Yang, P. et al. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine. Vet Microbiol 146, 17-23, doi: 10.1016/j.vetmic.2010.03.024 (2010).
40. Cox, F. et al. Matrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 Challenge. PLoS One 10, e0135723, doi: 10.1371/journal.pone.0135723 (2015).
41. Schneider-Ohrum, K. et al. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the eficiency of influenza virus-like particle vaccines in aged mice. Vaccine 29, 9081-9092, doi: 10.1016/j.vaccine.2011.09.051 (2011).
42. Miyaki, C. et al. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine 28, 2505-2509, doi: 10.1016/j.vaccine.2010.01.044 (2010).
43. Ichinohe, T. et al. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 82, 1754-1761, doi: 10.1002/jmv.21824 (2010).
44. Liu, G. et al. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 30, 6833-6838, doi: 10.1016/j.vaccine.2012.09.013 (2012).
45. Clegg, C. H. et al. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. PLoS One 9, e88979, doi: 10.1371/journal. pone.0088979 (2014).
46. Clegg, C. H. et al. Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci USA 109, 17585-17590, doi: 10.1073/pnas.1207308109 (2012).
47. Vasilakos, J. P. & Tomai, M. A. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines 12, 809-819, doi: 10.1586/14760584.2013.811208 (2013).
48. de Witte, C. J. et al. Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review. Gynecol Oncol 139, 377-384, doi: 10.1016/j.ygyno.2015.08.018 (2015).
49. Lynn, G. M. et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol 33, 1201-1210, doi: 10.1038/nbt.3371 (2015).
50. Smirnov, D., and Schmidt, J. J., Capecchi, J. T. & Wightman, P. D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29, 5434-5442, doi: 10.1016/j.vaccine.2011.05.061 (2011).
51. Shah, R. R. et al. The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance. J Pharm Sci 104, 1352-1361, doi: 10.1002/jps.24337 (2015).
52. Orr, M. T. et al. Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization. J Control Release 177, 20-26, doi: 10.1016/j.jconrel.2013.12.025 (2014).
53. Wiley, S. R. et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 3, 93ra69, doi: 10.1126/scitranslmed.3002135 (2011).
54. Desbien, A. L. et al. Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses. Biotechniques 54, 345-348, doi: 10.2144/000114041 (2013).
55. Young, B. E., Sadarangani, S. P. & Leo, Y. S. The avian influenza vaccine Emerfu. Why did it fail? Expert Rev Vaccines 14, 1125-1134, doi: 10.1586/14760584.2015.1059760 (2015).
56. Fox, C. B. & Haensler, J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 12, 747-758, doi: 10.1586/14760584.2013.811188 (2013).
57. Goff, P. H. et al. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol 89, 3221-3235, doi: 10.1128/JVI.03337-14 (2015).
58. Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-547, doi: 10.1038/nature09737 (2011).
59. Kulkarni, R. R. et al. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J Virol 88, 13990-14001, doi: 10.1128/JVI.02273-14 (2014).
60. Alving, C. R., and Peachman, K. K., Rao, M. & Reed, S. G. Adjuvants for human vaccines. Curr Opin Immunol 24, 310-315, doi: 10.1016/j.coi.2012.03.008 (2012).
61. Wang, W., Xie, H., Ye, Z., Vassell, R. & Weiss, C. D. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J Virol Methods 165, 305-310, doi: 10.1016/j.jviromet.2010.02.009 (2010).
62. Garcia, J. M., Lagarde, N., Ma, E. S., de Jong, M. D. & Peiris, J. S. Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J Clin Virol 47, 29-33, doi: 10.1016/j.jcv.2009.10.009 (2010).
63. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267 (1996).
64. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society, Series B 57, 289-300 (1995).